Seeing Is Believing
Currently out of the existing stock ratings of Mani Foroohar, 120 are a BUY (54.05%), 86 are a HOLD (38.74%), 16 are a SELL (7.21%).
Analyst Mani Foroohar, currently employed at LEERINK, carries an average stock price target met ratio of 57.03% that have a potential upside of 45.04% achieved within 243 days.
Mani Foroohar’s has documented 409 price targets and ratings displayed on 27 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on SRPT, Sarepta Therapeutics at 21-Jul-2025.
Analyst best performing recommendations are on FDMT (4D MOLECULAR THERAPEUTICS ).
The best stock recommendation documented was for FDMT (4D MOLECULAR THERAPEUTICS ) at 11/14/2022. The price target of $15 was fulfilled within 1 day with a profit of $1.51 (11.19%) receiving and performance score of 111.93.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Buy
$12
$9.61 (402.09%)
$16
1 months 9 days ago
(26-Jun-2025)
1/4 (25%)
$9.51 (381.93%)
292
Hold
$4
$1.61 (67.36%)
$5
2 months 20 days ago
(15-May-2025)
1/5 (20%)
$1.95 (95.12%)
81
Buy
$33
$30.61 (1280.75%)
$33
2 months 20 days ago
(15-May-2025)
3/7 (42.86%)
$30.95 (1509.76%)
884
Buy
$30
$27.61 (1155.23%)
$30
2 months 20 days ago
(15-May-2025)
0/6 (0%)
$27.95 (1363.41%)
Buy
$6
$4.05 (207.69%)
$4
1 years 10 months 30 days ago
(05-Sep-2023)
4/7 (57.14%)
$4.22 (237.08%)
196
Which stock is Mani Foroohar is most bullish on?
Which stock is Mani Foroohar is most reserved on?
What Year was the first public recommendation made by Mani Foroohar?